Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Meirav Chovav of Salomon Brothers lowered her rating on Biogen Inc. to "hold" from "buy" because disappointing
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury